JPMorgan analyst John Stansel downgraded Molina Healthcare (MOH) to Neutral from Overweight with a price target of $350, down from $378, after assuming coverage of the name. Entering 2025, the firm is “cautiously optimistic” that Medicaid rate updates can narrow the disconnect between rates and utilization and acuity. On the Affordable Care Act exchanges, the analyst sees enhanced advance premium tax credit expiration as likely driving potential headwinds to managed care originations with varying impact. JPMorgan views Centene’s (CNC) valuation as attractive and believes it incorporates a pessimistic view of the impact of ACA subsidy expiration in 2026. However, it sees a more balanced relative risk/reward for Molina Healthcare.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare Expands with New State Contracts
- Molina Healthcare awarded new contracts in Michigan, Idaho
- Lawmakers seek to break up PBMs from health insurers, WSJ reports
- Elevance Health price target lowered to $458 from $529 at Jefferies
- Molina Healthcare price target lowered to $312 from $348 at Jefferies